KDR and cancer: In addition, apratoxin S10 also inhibited the proliferation of cancer cells from highly vascularized tumors through the downregulation of RTKs, including VEGFR2, epidermal growth factor receptor (EGFR), met proto-oncogene (hepatocyte growth factor receptor) (MET), insulin-like growth factor 1 receptor β (IGF1Rβ), and fibroblast growth factor receptor 4 (FGFR4) [51].